Abstract
Spatial repellents (SR) that passively emanate airborne concentrations of an active ingredient within a space disrupt mosquito behaviors to reduce human-vector contact. A clinical trial of SC Johnson’s Mosquito Shield™ (Mosquito Shield) has demonstrated 33% protective efficacy against malaria in Kenya. Mosquito Shield lasts for one month, but a longer duration product would be advantageous for deployment by malaria control programs. SC Johnson’s Guardian™ (Guardian), is designed to provide longer continuous protection from disease-transmitting mosquitoes. We conducted an experimental hut trial to evaluate the efficacy of Guardian over 12 months and compared it to Mosquito Shield over one month against wild pyrethroid resistant malaria vector mosquitoes, using entomological surrogates of clinical efficacy to assess the potential public health utility of Guardian. The primary endpoint was the number of blood-feeding An. arabiensis, while secondary endpoints were number landing proportion of An. arabiensis mortality and proportion blood-fed. Over 12 months of continuous tests, Guardian reduced numbers of An. arabiensis blood-feeding by 83% (95% Confidence Interval (79 – 86)) and landing by 65% (59 – 70). Guardian also induced 20% mortality (18 – 22). Guardian was found to be superior to Mosquito Shield in reducing the number of blood-fed An. arabiensis, and had similar proportions of blood-fed mosquitoes and 24-hours mortality. Results indicate that Guardian effectively reduces blood-feeding and landing of wild pyrethroid resistant malaria vectors for 12-months and shows superior protective efficacy to Mosquito Shield on the blood-feeding endpoint. Experimental hut studies are suitable for comparative evaluations of new spatial repellent products because they precisely estimate entomological endpoints elicited by spatial repellents known to significantly impact vectorial capacity and disease transmission.
What is already known on this topic?
There is increasing evidence that spatial repellents have public health value. Randomized control trials have shown that SC Johnson Mosquito Shield™ (Mosquito Shield), a transfluthrin based spatial repellent, is effective in reducing malaria and dengue transmission. A WHO policy recommendation for the spatial repellent intervention class would follow a WHO-commissioned systematic review of the data from clinical trials.
Mosquito Shield is effective for 30 days but malaria transmission lasts for 6 to 12 months in most endemic regions. Therefore, a longer lasting product required only one deployment per transmission season would be more operationally feasible, especially in remote areas of Africa where malaria burden is highest.
What are the new findings?
This is the first study to provide evidence of a spatial repellent product that can reduce the number of wild pyrethroid resistant An. arabiensis blood-feeding by 83% and landing by 65% while inducing a 20% delayed mortality at 24 hours for a duration of one-year.
The study also demonstrated that Guardian was superior to Mosquito Shield (tested in RCTs) in reducing number of blood-fed An. arabiensis.
Impact on vector control practice or policy
Guardian meets the preferred product characteristics for a public health spatial repellent. It lasts a full year, and it does not require daily user interaction. This likely will result in higher adherence and coverage with lower operational cost for implementation compared to Mosquito Shield or other shorter-duration spatial repellents.
Guardian is expected to have public health value by impacting disease transmission when used as a vector control tool against malaria because it showed superior performance when compared to Mosquito Shield, which has demonstrated malaria reduction in clinical trials.
Competing Interest Statement
The authors JKS, WSN, EM, HAN, NOM, APM and SJM conduct product evaluations for companies that produce vector control products including S.C. Johnson & sons, Inc. MRC and TMM are employed by S.C. Johnson & Son, Inc, Racine, Wisconsin.
Funding Statement
The study was supported by S. C. Johnson & Son, Inc, Racine, Wisconsin.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
